Glenmark Pharmaceuticals executes agreement to transfer its API business
Glenmark Pharmaceuticals has executed business purchase agreement for transfer of the company’s API business to its wholly owned subsidiary — Glenmark Life Sciences on October 9, 2018. The transaction is expected to be completed in the next 2-3 months.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.